Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $928,950.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.89, for a total transaction of $928,950.00. Following the sale, the chief executive officer now directly owns 575,661 shares of the company’s stock, valued at $9,722,914.29. This represents a 8.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total value of $30,479.04.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.32, for a total value of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.80, for a total value of $350,839.00.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.53, for a total transaction of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total transaction of $2,891,000.00.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $17.04 on Monday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm’s fifty day simple moving average is $16.09 and its 200 day simple moving average is $12.42. The stock has a market cap of $1.93 billion, a P/E ratio of -11.14 and a beta of 1.47. Centessa Pharmaceuticals plc has a twelve month low of $5.58 and a twelve month high of $18.74.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. As a group, research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CNTA shares. Jefferies Financial Group increased their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Guggenheim increased their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 15th. BMO Capital Markets upped their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, Oppenheimer restated an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $25.83.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CNTA. Price T Rowe Associates Inc. MD lifted its stake in shares of Centessa Pharmaceuticals by 16.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after purchasing an additional 418,615 shares during the period. Nantahala Capital Management LLC bought a new position in Centessa Pharmaceuticals in the second quarter worth $4,064,000. Driehaus Capital Management LLC lifted its position in Centessa Pharmaceuticals by 89.5% during the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after buying an additional 987,997 shares during the period. GSA Capital Partners LLP boosted its holdings in shares of Centessa Pharmaceuticals by 66.1% during the 3rd quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock valued at $1,498,000 after buying an additional 37,275 shares in the last quarter. Finally, First Light Asset Management LLC grew its position in shares of Centessa Pharmaceuticals by 59.2% in the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after buying an additional 1,778,515 shares during the period. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.